When the call ended, I sat there listening to the pipes knock and felt for the first time that day the full scale of what was now required of me. Not the public side. I knew how to do that. Crisis statements, legal coordination, investor containment, board leverage—those were problems with edges. Solvable, or at least manageable. Harder by far would be the domestic archaeology: telling Lily in a way that did not wreck her faith in everything at once, helping Noah navigate anger without turning it inward, removing Mark from the grammar of our house one decision at a time.
I dressed in a spare set of clothes Arthur arranged to have sent up from one of the apartments we kept for on-call executives. Navy trousers. Cream blouse. Black blazer. It would do.
Then I went to war.
The board meeting convened in less than an hour.
Half of them arrived in person, the rest by secure video. Their faces tiled across the screens: concern, indignation, embarrassment, greed. Board members are like weather systems. Some rain because they are moved, some because pressure changes. I took the seat at the head of the table not because I needed to assert anything but because for too long I had allowed Mark to occupy it during public sessions to preserve the fiction that operational charisma mattered more than ownership and strategy. That fiction had just bled out on marble.
Arthur presented first. Cleanly. Financial irregularities, traced transfers, concealed property, inappropriate relationship with an employee, reputational exposure, probable breaches of fiduciary duty, likely criminal liability. He did not dramatize. Facts are more frightening when allowed to stand upright.
The board reacted in factions.
Two members tried immediately to pivot toward damage control language and “protecting market confidence.” One elderly donor representative looked personally wounded, as if Mark’s adultery had somehow been committed against the annual gala. A venture-capital appointee asked whether the MRI contract itself was compromised. I told him no because I had personally kept Mark away from it for precisely the reasons now becoming public.
Then Martin Feld, who chaired the compliance committee and had disliked being outmaneuvered by Mark for years, leaned back and said, “What leadership alternative are you proposing, Catherine?”
Not if. What.
Good.
“David Chen as interim chief executive,” I said.
There was instant pushback.
“He’s a clinician.”
“He has no investor-relations experience.”
“He is temperamentally unsuited for diplomacy.”
“That,” I said, “is one of his better qualities.”
They looked at me.
